Novartis Zelmac
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
FDA Gastrointestinal Drugs Advisory Committee will meet June 26 in Gaithersburg, Md. to discuss NDA 21-200 for Novartis' Zelmac (tegaserod) for the treatment of abdominal pain and discomfort, bloating and altered bowel function in patients with irritable bowel syndrom